Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index (Q47297341)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2007

Language	Label	Description	Also known as
English	Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index	scientific article published in January 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

insulin detemir

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Katarina Raslová

1

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

Soren Can Tamer

2

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

Per Clauson

3

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

Diane Karl

4

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

27

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

4

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

279-285

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

Tissue selectivity of insulin detemir action in vivo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

At last, a weight neutral insulin?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes, obesity, and the brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of improved glycemic control on complications in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin detemir: from concept to clinical experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17358100

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00044011-200727040-00007

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

release_4panffg6l5dc3eu4yls64ohvee

1 reference

https://api.fatcat.wiki/v0/release/4panffg6l5dc3eu4yls64ohvee

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 January 2018

http://europepmc.org/abstract/MED/17358100

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47297341&oldid=2150682056"